Research status of p53 in the pathogenesis of 5q-syndrome

羊文莉,佟红艳

DOI: https://doi.org/10.3760/cma.j.cn511693-20200912-00192

2021-01-01

Abstract:5q-syndrome is a distinct subtype of myelodysplastic syndrome (MDS). Its clinical manifestations were anemia, normal or increased platelet count and bone marrow blasts<5%. Patients with 5q-syndrome have a comparatively better prognosis than other subtypes of MDS. As research progresses, the pathogenesis of 5q-syndrome is gradually revealed. The haploinsufficiency of CSNK1 A1, RPS14, EGR1 and other genes in the long arm of chromosome 5 (5q) are the molecular mechanisms of its phenotype, and the absence of these genes are related to p53, which is the expression product of TP53. Besides, the mutation rate of TP53 in MDS patients with chromosome 5 abnormalities is higher than the total MDS patients. Thus p53 plays an important role in pathogenesis of 5q-syndrome, which has become a potential therapeutic target. And the mechanisms of lenalidomide, as the first-line drug for 5q-syndrome, is also related to p53. This article provides an overview of the pathogenesis of p53 in the 5q-syndrome, including molecular mechanisms of the haploinsufficiency of RPS14、 CSNK1 A1、 EGR1 and TP53 mutation, as well as the effects of lenalidomide targeting on p53.